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Abstract
Despite the remarkable number of scientiﬁc breakthroughs of the last 100 years, the treatment of neurodevelopmental
disorders (e.g., autism spectrum disorder, intellectual disability) remains a great challenge. Recent advancements in
genomics, such as whole-exome or whole-genome sequencing, have enabled scientists to identify numerous
mutations underlying neurodevelopmental disorders. Given the few hundred risk genes that have been discovered,
the etiological variability and the heterogeneous clinical presentation, the need for genotype—along with phenotype-
based diagnosis of individual patients has become a requisite. In this review we look at recent advancements in
genomic analysis and their translation into clinical practice.
Introduction
The past decade has seen a rapid development of pre-
cise technological and methodological advancements in
genetics and genomics, thus allowing an unprecedented
identiﬁcation of mutations that are involved in complex
neurodevelopmental conditions. Neurodevelopmental
disorders (NDDs) affect more than 3% of children
worldwide and can be attributed to mutations at over
1000 loci1.
Understanding the etiology of NDDs faces many chal-
lenges that range from delineating the heritable genetic
components to deﬁning individual factors that predispose
to NDD risk and identifying the precise mechanisms
through which these factors together lead to the disorder2.
In addition, the clinical heterogeneity of NDDs make
diagnosing a lengthy and costly process, complicating the
quest for personalized medicine. However, the identiﬁ-
cation of bona ﬁde genetic risk factors and the use of
functional genomics to progress from mutation to phe-
notype represent a solid foundation for the development
of individualized therapeutic approaches. In this review,
we begin by mentioning some features of these disorders
and continue by emphasizing the importance of genomics
in determining the etiology of NDDs. We then describe
advantages and limitations in the use of animal or stem
cell models to study patient-speciﬁc genetic mutations.
Finally, we discuss successful examples of translational
research creating an evidence-based framework of how
personalized medicine can advance the treatment of
NDDs.
Neurodevelopmental disorders
NDDs are a group of early onset neurological disorders,
including autism spectrum disorders (ASD), intellectual
disability (ID) and language disorders among others.
ASDs are characterized by early dysfunction in social
interactions, communication deﬁcits, and the presence of
repetitive and restricted behaviors3. ASDs, with an esti-
mated prevalence of 1 in 68 births3, represent an issue of
public concern. Typically, ASDs have been classiﬁed into
syndromic—Rett syndrome (RS)4, Fragile X syndrome
(FXS)5, and tuberous sclerosis (TSC)6—and non-
syndromic. Evidence suggests that the causes involve both
genetic and environmental factors7. Patients diagnosed
with ASD often present with other comorbidities such as
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intellectual disability (ID)8, epilepsy9, and motor
abnormalities10. Intellectual disability affects ~1.5–2% of
the Western population11. The severe forms of ID are
thought to have a genetic origin, but in at least 50% of
cases, the cause remains elusive. Over the past years many
autosomal or X-linked mental retardation genes have
been identiﬁed12, with FMR1 (FXS) being one of the most
common inherited monogenic causes of ID and ASD in
male patients13. The core features of ASD and ID often
coexist with recurrent seizures or epilepsy. Epileptic sei-
zures are due to abnormal neuronal activity such as
excessive excitation or hypersynchronization, which can
occur as a result of developmental defects or due to brain
insults (e.g., trauma, stress, etc.) later on in life. With over
65 million people affected worldwide, epilepsy is the most
common, chronic neurological disorder14. Although in
many cases seizures can be controlled by existing anti-
epileptic drugs, the treatment gap is still large15. Genetic
underpinnings for epilepsies have been long recognized
and over the past 20 years a signiﬁcant number of
epilepsy-risk genes have been identiﬁed16,17.
The genetics of NDDs
On average, a newborn acquires between 50 and 100
new genetic variants, resulting in 0.86 new amino acid-
altering mutations (i.e., de novo mutations) per indivi-
dual18. Given such a high individual variability, a plethora
of variants associated with NDDs have been found in
hundreds of different genes, ranging from single nucleo-
tide changes (single nucleotide variants (SNV)) to loss or
gain of up to thousands of nucleotides (copy number
variants (CNV)).
Sequencing of the human and other mammalian gen-
omes has provided an important set of tools to start
understanding the human genetic variation. The ﬁrst
steps to elucidate the genetic heterogeneity of NDDs were
Fig. 1 Genomic sequencing guides the way from patient DNA to personalized medicine. a DNA from patients diagnosed with NDDs used for
sequencing; FXS Fragile X Syndrome, RS Rett Syndrome, PMDS Phelan McDermid Syndrome, DS Dravet Syndrome, AS Angelman Syndrome, ASD
autism spectrum disorder. b Next-generation sequencing can be used to decipher the genetic code within exons (dark blue section—whole-exon
sequencing) or throughout the entire genome (dark and light blue section—whole-genome sequencing). Mutations are identiﬁed in a series of
genes with predisposition to NDDs (pink ovals). c The mutations are regenerated in models (mice, organoids, or hESC-derived neurons) in order to
understand their underlying mechanism. d Disease modeling reveals targets that enable the implementation of personalized medicine. ASO
(antisense oligonucleotides—gray panel) and BCAA (branched chain amino acids—beige panel) are two examples of personalized therapies probed
in mouse models. mGLUR (metabotropic glutamate receptor) activity (green panel) needs to be decreased in FXS and increased in PMDS. Drug
repurposing (blue panel) enables the usage of the same drug for different diseases due to novel mechanisms identiﬁed
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done by using karyotyping or ﬂuorescence in situ hybri-
dization (FISH). As the need for more accurate detection
of nucleotide variations in the context of developmental
disabilities grew, chromosome microarray (CMA) tech-
nology was developed and rapidly implemented as part of
ﬁrst-line evaluation for children with a NDD19,20. CMA
set the stage for genetic variation detection, but the
advent of whole-genome and whole-exome sequencing
(WGS and WES) led to the identiﬁcation of many
inherited and de novo germline variants that signiﬁcantly
contribute to total NDD risk21–24 (Fig. 1a, b). In the case
of ASD for instance, it is estimated that rare genetic
mutations, both de novo and inherited, are causal in ~11%
of simplex cases25. Similarly, common inherited genetic
variants contribute substantially to ASD risk (49%);
however, the individual common genetic variant liability
is lower than that for rare genetic mutations26. Likewise,
in the case of epilepsy, rare CNVs have been shown to
explain ~3% of individuals suffering from idiopathic
generalized epilepsy27. In addition, ~300 de novo muta-
tions were identiﬁed in patients suffering from epileptic
encephalopathies. These mutations emphasize the con-
vergence on speciﬁc biological pathways due to their
enrichment in certain gene sets including genes regulated
by the fragile X protein28. Finally, germline mutations do
not explain all NDD cases, indicating that other genetic
defects also come into play. For example, postzygotic (i.e.,
somatic) mutations explain a signiﬁcant proportion of
NDD cases29–31. Along with the previously identiﬁed
CNVs, such mutations have meaningful implications for
risk prediction, diagnosis and patient management32.
Thus, the abovementioned technologies represent
powerful tools for the molecular genetic dissection of
patients affected by NDDs. Their introduction into clin-
ical practice and association with routine phenotype-
driven diagnosis holds promise for personalized diagnosis
and therapy of NDDs.
The promise of genetics
The early occurrence of genetic glitches and the rela-
tively late onset of symptoms that enable the diagnosis of
NDDs, represent a major pitfall in identifying the cause
and delivering the right kind of therapy. To complicate
things further, for most NDDs, therapies hinge largely on
behavioral or educational interventions33 and on treating
associated rather than core symptoms of the disorder.
Thus, for the majority of people with NDDs, the outcomes
are poor or very poor in adulthood34. Given such chal-
lenges, we must ask how genetics may contribute to their
improvement.
First and foremost, genetic testing can lead to active
monitoring and early intervention, even before the onset
of the disorder. Furthermore, knowing the genetic cause
of a disorder may reveal the role of a speciﬁc biological
pathway in its onset. Thus, targeted pharmacological
interventions could be made with already existing drugs.
Studies reported that 55% of 187 genetic ﬁndings led to
changes in clinical management35 and 10 out of 118
probands undergoing WES beneﬁted from a revised
diagnosis and clinical assessment36. Similarly, WES with
targeted gene analysis (e.g., SCN1A) inﬂuenced decisions
on antiepileptic drug selection and reconsideration of
surgical interventions37. Lastly, since NDDs are associated
with cognitive and behavioral abnormalities, genetic
information can guide the choice of behavioral treat-
ment38. However, despite these advantages, the multiple
guidelines proposing the use of genetic testing for indi-
viduals with NDDs are not implemented routinely in
clinical practice20. This lack of use is either due to scarcity
of resources or due to a lack of medical staff prepared to
analyze and interpret genetic results. To circumvent this
issue, a proper dissemination of up-to-date ﬁndings about
NDD genetics to clinical staff is desirable. In addition,
genetic counseling should inform parents about recur-
rence risk assessment.
Modeling NDDs: potentials and limitations
An ideal model of a human disorder is characterized by
construct validity (model mimics the genetic insult that
causes the disease), face validity (the model’s phenotype
resembles that of the human disease), and predictive
validity (the model and the patients respond similarly to
certain treatments). Several systems (cells, rodents, pri-
mates) have been used to generate models of NDDs that
can partially reproduce disease features and can be of
interest for understanding underlying mechanisms
(Fig. 1c).
The most favored model organism, the mouse, has been
extensively employed for modeling neurological disorders
with a known genetic cause, such as FXS (Fmr1 KO)
(FXS)39, Dravet syndrome (DS-Scn1a KO)40, ASD Nrxn1a
KO41, Nlgn3 KO42, Phelan-McDermid syndrome (PMDS-
Shank 3 KO)43 or RS (Mecp2 KO)44. Mice share 95–98%
of their genomic information with humans, have a rela-
tively rapid reproduction time, are cost-effective and allow
scientists to precisely manipulate their genome in a
temporal/spatial speciﬁc manner. However, mice also
present with important limitations. For example, assess-
ment of higher brain functions, such as language and
facial recognition, is difﬁcult in large screens. To over-
come some of these limitations, non-human primates can
be employed to model complex behavior and higher
cortical functions45, whereas zebraﬁsh and invertebrates
can be used for high-throughput genetic screens46.
Alongside animal models, in vitro reprograming of stem
cells has enabled the generation and analysis of human
neurons. Employing either human embryonic stem cell
(hESC)-derived or human induced pluripotent stem cell
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(hiPSC)-derived neurons, researchers have recapitulated
several neuronal synaptic defects for monogenic forms of
NDDs such as RS47, FXS48, Prader-Willi and Angelman
syndromes (AS)49, PMDS50, DS51 and Timothy syndrome
(TS)52,53. The experimental tractability, the ability to
model diseases directly from affected individuals and the
unlimited source of cells are just some of the advantages
of stem cell-based models. Conversely, the high hetero-
geneity among iPSC clones, the immature identity of
neurons differentiated in vitro, the lack of high-order
connectivity and the difﬁculty to model lamination in a
2D system are some of the obvious shortcomings of iPSC-
derived disease models. Fortunately, recently several
researchers have developed protocols for the generation
of 3D cortical organoids (mini-brains/spheroids), provid-
ing avenues to study features of cortical lamination and
brain development in vitro54,55, thus contributing addi-
tional tools for studying the mechanisms underlying
NDDs52,56.
Bridging the gap between research and the clinic
—personalized therapeutic approaches for NDDs
Axiomatically, the biggest advantage of genetic studies
is to provide clues about the underlying neurobiology of
NDDs and to transition those clues into clinical practice
(Fig. 1d).
At present, the available treatments for NDDs consist of
a combination of behavioral therapies57 and drugs
approved for ameliorating comorbidities such as irrit-
ability and anxiety, while in many cases the core symp-
toms of NDDs remain unsolved.
However, the combination of genetics and functional
analysis led to the discovery of several molecular pathways
involved in NDDs that were targeted to evaluate novel
therapeutic strategies. Particularly, inhibiting the
mechanistic target of rapamycin (mTOR) rescues phy-
siological, morphological and behavioral abnormalities in
mice modeling diseases associated with protein transla-
tion defects such as TSC58, PTEN- associated macro-
cephaly59 or 15q11-13 duplication syndrome60. Multiple
clinical trials are investigating the pharmacokinetics and
pharmacodynamics of rapamaycin and its analogs (sir-
olimus, everolimus) for treating TSC with associated
ASD61,62. Likewise, increasing levels of (IGF1) -like
growth factor 1 and brain-derived neurotrophic factor via
transcriptional modulation improves physiological and
behavioral anomalies in RS mouse models63,64 and IGF1
administration leads to a higher endurance to social and
cognitive testing in patients with RS65 or PMDS66.
Modulation of the excitation/inhibition ratio by
employing antagonists of mGluRs or agonists of GABA A
and GABA B receptors, has also been considered as a
potential strategy to treat NDDs67. However, contrary to
what was predicted by a decade of studies in FXS animal
models, administration of mavoglurant, an mGluR5
antagonist68, or arbaclofen, a GABA B receptor ago-
nist69,70, to adolescents and adults with FXS showed no
signiﬁcant improvement in behavioral traits in a rando-
mized, double-blind, placebo-controlled phase 2 trial.
Conversely, in a mouse model of PMDS with complete
deletion of Shank3, researchers reported decreased
mGluR5 signaling in the striatum and cortex. Adminis-
tration of a benzamide derivative resulted in augmenta-
tion of mGluR5 activity and rescue of functional and
behavioral defects in mice. Thus, pharmacological treat-
ments aimed at increasing mGluR5 activity may represent
an option for patients with SHANK3 mutations71,72. The
contrasts between mGluR5 activity in FXS and PMDS
suggest that the dysfunction leads to distinct phenotypes
in different brain regions/genetic backgrounds. Hence,
genetically discriminating between different forms of
NDDs and identifying the convergence of the common
molecular pathways underlying NDD pathophysiology are
important goals (Fig. 1d).
Recently, new therapeutic strategies have been
designed based on genetic ﬁndings. For example, AS is
mostly caused by loss-of-function mutations in the
maternal allele of the imprinted UB3A gene, while the
paternal allele is silenced by a long noncoding RNA
(UBE3A antisense transcript). Using antisense oligonu-
cleotides (ASOs) (Fig. 1d) the paternal allele was unsi-
lenced, thereby restoring the UB3A protein levels and
leading to improvement in cognitive deﬁcits in an AS
mouse model73. Following a similar rationale, ASOs are
used for restoring normal levels of MeCP2 and rescuing
neurological deﬁcits in mice carrying an extra copy of
Mecp274. Replacing a defective gene may also be
achieved by gene therapy using adeno-associated virus
(AAV) vectors75. However, making ASOs and AAV
amenable to translation into clinical trials is challenging
due to their safety, pharmacokinetics and distribution in
the brain76. In a similar vein, WES of consanguineous
families with ASD, ID and epilepsy led to the identiﬁ-
cation of mutations in the gene BCKDK (Branched
Chain Ketoacid Dehydrogenase Kinase), encoding an
enzyme regulating the catabolism of the branched-chain
amino acids (BCAAs). The Bckdk mouse model displays
an abnormal brain amino acid proﬁle and dietary sup-
plementation with the missing BCAAs reverses certain
neurological phenotypes (Fig. 1d). Furthermore, BCAA
dietary supplementation in patients led to normalization
of plasma BCAA levels, demonstrating the potential of
BCAA supplementation as a therapy in patients with
BCKDK mutations77,78.
In addition to identifying new targets for therapy,
genetic ﬁndings are useful for personalizing existing
pharmacotherapy or behavioral interventions. In this
sense, WES with targeted gene analysis (e.g., SCN8A,
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KCNQ2) is an effective diagnostic tool for patients with
epilepsies as it can inﬂuence anti-epileptic drug selection,
adverse effect minimization and consideration for surgery,
based on each patient’s genetic script37. In the case of
people with SHANK3 deletions, they tend to have more
advanced receptive communication skills than verbal
language ability79 and therefore could beneﬁt from assis-
tive communication strategies that may not have been in
mind unless the genetic cause of their ASD was known.
Recently, a very common trend uses genetic ﬁndings for
the application of targeted drug repurposing based on
single gene defects (Fig. 1d). Such an approach already
shows promise for personalizing therapies for epilepsy
cases arising from gain-of-function mutations in ion-
channel subunit genes (e.g., GRIN2A, GRIN2B, SCN8A).
Nonetheless, important barriers remain in order to
translate these approaches to non-ion channel epilepsy
genes and loss-of-function mutations80,81. Likewise,
recent observations indicate that metformin, a worldwide
ﬁrst-line therapy for type 2 diabetes, rescues core phe-
notypes in adult FXS mice due to normalization of ERK
signaling, eIF4E phosphorylation and matrix metallopro-
teinase 9 expression (MMP-9)82. Given that the previously
mentioned clinical trials with mGluR5 antagonists have
failed, metformin represents a new therapeutic avenue for
clinical studies involving FXS patients. Administration of
oxytocin, which is a peptide usually administered to
initiate uterine contractions that also appears to be
involved in modulating social behavior, improves ASD-
like social deﬁcits in several mouse models83 and in a
Shank3-deﬁcient rat84, but the clinical effectiveness of
oxytocin on ASD should still be considered tentative due
to mixed ﬁndings85.
Conclusion
The quick development of novel and efﬁcient sequencing
technologies made the identiﬁcation of genetic causes for a
number of NDDs possible. Using these techniques, an
underlying genetic cause of many NDD cases can be
identiﬁed. This progress allows the design of personalized
therapeutic strategies and the implementation of genetic
counseling. Furthermore, studies employing animal and
human cell models carrying speciﬁc genetic glitches are
underscoring potential novel therapeutic approaches.
In the past few years, potential treatments derived from
genetic and functional analysis made it to clinical trials.
Although several clinical trials have failed, the treatment of
some NDDs seems much closer. Due to the very complex
nature of NDDs, interdisciplinary approaches combining
genetics, functional genomics, robust biological models and
objective measures of response, such as biomarkers86, as
well as the capability of researchers and clinicians to work
side by side, will be essential.
Data for this review was collected by typing the fol-
lowing keywords into PubMed: genomics, genetics, per-
sonalized therapy, neurodevelopmental disorders (all in
combination with NDDs, ASD, ID).
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